Acute antibody-mediated rejection (AMR) occurs in a small minority of sensitized liver transplant recipients. Although histopathologic characteristics have been described, specific features that could be used: a) for a generalizable scoring system; and b) to trigger a more in-depth analysis are needed to screen for this rare but important finding. Toward this goal, we created a training and validation cohort from 3 high volume liver transplant programs of putative acute AMR and control cases that were evaluated blindly by 4 independent transplant pathologists. Evaluations were performed on H&E sections alone without knowledge of either serum DSA results or C4d stains. Routine histopathological features strongly correlated with severe acute AMR included portal eosinophilia, portal vein endothelial cell hypertrophy, eosinophilic central venulitis, central venulitis severity, and cholestasis. Acute AMR inversely correlated with lymphocytic venulitis and lymphocytic portal inflammation. These and other characteristics were incorporated into models created from the training cohort alone. The final Acute-AMR (aAMR) score (portal vein endothelial cell hypertrophy + portal eosinophilia + eosinophilic venulitis / lymphocytic portal inflammation + lymphocytic venulitis) exhibited a strong correlation with severe acute AMR in the training (OR=2.86, p<0.001) and validation cohort (OR=2.49, p<0.001). SPSS tree classification was used to select 2 cutoffs, one that optimized specificity at a score >1.75 (sensitivity = 34%, specificity = 87%) and a second that optimized sensitivity at a score >1.0 (sensitivity = 81%, specificity = 71%). In conclusion, routine histopathological features of aAMR score can be used to screen for acute AMR on routine H&E in indication liver transplant biopsies, however, a definitive diagnosis requires
INTRODUCTION
The first evidence that antibodies can cause acute injury/rejection (antibodymediated rejection; AMR) in human liver allografts was observed in ABO-incompatible cadaveric, brain-dead whole organ donors (1, 2) . Antibody and complement deposition, platelet-fibrin thrombi, micro-vasculitis, and arteritis were typical and expected histopathological findings (1) , based on previous observations in ABO-incompatible renal allografts (3) and in ABO-compatible renal allografts harboring alloantibodies (4, 5) .
It was recognized early on, however, that human liver allografts were highly resistant to acute AMR from preformed HLA alloantibodies compared to kidney allografts (6) . This relative resistance was attributed to: the liver's inherent "tolerogenic" properties, the difficultly detecting antibody and complement tissue deposits, the paucity of typical histopathological findings (6) and, even when damage was present, to the noticeably diminished severity of injury compared to ABO-incompatible liver transplants (7, 8) . Relative hepatic resistance to AMR has been attributed to: a) secretion of soluble HLA class I molecules that form immune complexes with alloantibodies, which are then cleared by Kupffer's cells; b) Kupffer cell phagocytosis of platelet aggregates, immune complexes, and activated complement components (9) ; c) limited distribution of HLA class II expression in the microvasculature; d) large liver size and dual hepatic vasculature; and e) marked hepatocyte regenerative capacity after injury [reviewed in (7, 8) ]. In addition, the inferior sensitivity and specificity of cell-based cytotoxic antibody detection methods impaired prior investigators abilities to find associations between HLA antibodies and adverse patient and graft outcomes (1, 7, 8) .
Nevertheless, in the late 1980's and early to mid-1990's HLA class I and II antibodies, as measured in cytotoxic cell-based assays, were suspected to cause or substantially contribute to acute and chronic liver allograft rejection (7, (10) (11) (12) (13) . In addition, experimental rat studies clearly showed that extreme sensitization (14, 15) could override the liver's natural resistance and defense mechanisms. Similar observations were made in humans and risk factors for acute liver allograft AMR included high-titer pretransplant sensitization with persistence of serum alloantibodies after transplantation. When acute liver allograft AMR ensued, refractory thrombocytopenia, circulating immune complexes, and severe liver injury were then seen (7, 11) .
Recent studies using more sophisticated and sensitive (16) solid phase donorspecific HLA alloantibody (DSA) detection methods have confirmed and extended earlier studies with cytotoxic cell-based assays, even though the two tests have been documented to sometimes produce substantially different results on the same serum samples (17) . These confirmed findings include: 1) the liver allograft's relative resistance to AMR (18, 19) associated with the rapid disappearance of the vast majority of low to moderate MFI class I and II alloantibodies (11, 17, 18) ; and 2) an association of acute AMR with high-titer alloantibodies that most-often persist after transplantation and result in refractory thrombocytopenia and acute liver injury that can evolve into combined acute antibody-mediated and T-cell-mediated rejection. Inadequately treated, the end result can be chronic or ductopenic rejection (17, (20) (21) (22) (23) (24) . Solid phase DSA analyses have also shown an association between multiple IgG subclasses, especially when alloantibodies of the IgG3 subclass are present, and chronic rejection and diminished allograft survival (25) . These newer serum assays have also facilitated a closer correlation between histopathological findings and serum DSA characteristics (18, 23, 24, 26) .
Histopathological patterns of injury associated with acute liver allograft AMR include organ-specific findings such as portal edema, ductular reaction, eosinophilia, hepatocyte swelling and hepatocanalicular cholestasis, and histopathological findings similar to those seen with acute AMR in other solid organ allografts such as marked (portal) microvascular endothelial cell hypertrophy and monocytic/histiocytic, eosinophilic, and neutrophilic (portal) microvasculitis. During the early stages, the constellation of findings can resemble preservation/reperfusion injury or biliary stricturing, but often quickly progress to acute "cellular" or T-cell-mediated and finally chronic rejection (8, 11, 22-24, 26, 27) . Detection of microvascular complement deposition with C4d staining has been a valuable adjunct to the histopathological evaluation for acute AMR in all solid organ allografts, but C4d staining should not be used in isolation to establish an AMR diagnosis in liver allografts [reviewed in (27) (28) (29) ].
Finally, although severe acute AMR is rare, unrecognized it can lead to allograft failure (23, 30, 31) , as evidenced by its substantial contribution to ~ 10-20% of previously idiopathic early allograft failures (<90 days post-transplant) in sensitized patients (24) . Early recognition of acute AMR can prompt plasmapheresis (32) and plasma cell-specific therapy in rare patients and may result in improved outcomes (23, 30) . Toward the goal of facilitating earlier diagnosis of severe acute liver allograft AMR, this study was designed to identify and validate a limited constellation of routine histopathological features in the form of a generalizable scoring system on liver biopsy H&E analysis that can be easily used to trigger a more thorough clinicopathological evaluation (serum DSA testing, tissue C4d staining, and exclusion of other causes of a similar type of injury) needed to establish the diagnosis with certainty.
MATERIALS AND METHODS

Case Selection & Study Design:
Previous University of Pittsburgh Medical Center (UPMC) studies examined the effect of a conventional lymphocytotoxic crossmatch on patient and allograft survival (7) and the utility of C4d staining in primary liver allograft recipients (27) . As part of these prior studies a constellation of severe histopathological findings associated with acute AMR was described (27) . Although our final model produced a linear score, the output was not thought to be linearly associated with the ability to predict AMR. Therefore, we employed SPSS 16.0 to determine predictive cutoffs using tree classification. This was performed on the training cohort data from all 4 blinded pathologists before the validation cohort data was available for analysis and not modified after its completion. Significance was always defined as a P<0.05. SAS 9.1 was used for all statistical analyses except SPSS 16.0 was utilized for tree classification.
RESULTS
Patient characteristics for the 3 cohorts are presented in Table 1 . The cohorts were chosen differently because of local care standards, therefore, intergroup differences existed, but because of the blinded nature of analysis, none were felt to substantially influence the results. Table 2A shows pretransplant T-cell cytotoxic crossmatch data from UPMC cases according to C4d staining; of the 13 diffusely C4d positive cases 38% were T-cell crossmatch positive, whereas the remainder was T-cell crossmatch negative. All C4d-negative cases/biopsies had a negative T-cell cytotoxic crossmatch except one. Table   2B shows the pretransplant DSA correlation with C4d staining in the Edinburgh cases. lymphocytic portal inflammation and lymphocytic venulitis (Figure 2 ). Although cholestasis was not associated with DSA injury when all 4 pathologists scores were utilized in the training cohort, when particular attention was refocused to distinguish hepatocanalicular cholestasis from centrilobular hepatocyte lipofuscin deposition, an association was found in the validation cohort. In addition, the coefficients of concordance improved significantly after learning from the training cohort was followed by evaluation of the validation cohort.
Next, multiple models were created from the training cohort data alone, but Next tree classification was utilized on the training cohort to optimize the specificity for one cutoff and sensitivity for the other cutoff of the aAMR score ( Figure 5 ).
Sensitivity in the validation cohort increased from 34% to 81% when the cutoff used decreased from >1.75 to >1 respectively. Specificity in the validation cohort also decreased from 87% and 71% when the cutoff used decreased from >1.75 and >1
respectively. In addition, the Kendall's coefficient of concordance between pathologists was 0.61 in the training and 0.50 in the validation cohorts. Screening for acute AMR can be easily accomplished by using parameters included in the aAMR score on indication liver biopsies. We recommend using features identified in the overall score to screen for putative cases. Eosinophilia had the strongest correlation with acute AMR of any single histologic characteristic (HR = 4.37, p<0.001)However, using the aAMR score in clinical practice, or specifically examining cases for AMR-associated features, should facilitate identification of the most severe cases of AMR. We opted, therefore, for high specificity and set a relatively high threshold aAMR score of >1.75 to raise significant concern for an acute AMR diagnosis.
This approach is recommended because of potential consequences of AMR therapy and to avoid over-diagnosis, which would inhibit widespread acceptance of a diagnosis that many already view with skepticism. Eventually, however, to improve sensitivity biopsies with scores >1 should be subjected to C4d staining and serum DSA testing should be carried out to substantiate or refute a putative AMR diagnosis. This will enable recognition of the entire spectrum of changes associated with AMR.
This study evaluated acute AMR at a more granular level than prior appraisals in an effort to help recognition of the most severe form of acute AMR. However, there are several shortcomings. One, training and validation cohorts were selected differently because of local standards of care. Two, there are no current Banff criteria for acute AMR, and therefore previous descriptions were used to select cases (27) . and 4) reasonable exclusion of other causes of a similar type of injury (24) . However, over time our understanding of acute AMR and C4d staining protocols will improve and molecular signatures of liver allograft AMR will be developed. As these advances unfold we expect that, like renal transplant pathology, histopathological features of acute and chronic liver AMR will be even more precisely defined, and C4d negative AMR will be described.
In summary, routine histopathological features in the aAMR score can be used to suspect the most severe form of acute AMR, a diagnosis that requires further substantiation by donor-specific HLA alloantibody testing, C4d staining, and exclusion of other insults. In the future, more subtle forms of DSA induced liver allograft injury will likely be discovered and described. 
